🇺🇸 FDA
Patent

US 11602559

HIV-1 Env fusion peptide immunogens and their use

granted A61KA61K2039/545A61K2039/6037

Quick answer

US patent 11602559 (HIV-1 Env fusion peptide immunogens and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/545, A61K2039/6037, A61K2039/6081, A61K39/12